Related Experiment Videos
Could knee inflammatory synovitis be induced by pembrolizumab?
Fade Mahmoud1, John T Wilkinson2, Alison Gizinski3
11 Department of Internal Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Summary
Pembrolizumab, an immunotherapy drug, can rarely cause synovitis, an inflammatory joint condition. Early recognition and treatment are crucial to prevent long-term joint damage in cancer patients.
Area of Science:
- Oncology
- Immunology
- Rheumatology
Background:
- Pembrolizumab is a humanized monoclonal antibody targeting the PD-1 pathway, used to reactivate T cells for cancer treatment.
- Cancer immunotherapy with immune checkpoint inhibitors is increasingly prevalent in clinical practice.
Observation:
- Immune-related adverse events (irAEs) are known complications of PD-1 inhibitors.
- Common irAEs include colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis.
- Pembrolizumab-induced synovitis is a rare irAE that has been infrequently reported.
Findings:
- This report highlights pembrolizumab-induced synovitis as a rare but significant immune-related adverse event.
- The condition involves inflammation of the synovium, potentially leading to joint damage if untreated.
Implications:
- Physicians must maintain a high index of suspicion for synovitis in patients receiving pembrolizumab therapy.
- Prompt diagnosis and management of pembrolizumab-induced synovitis are essential to mitigate the risk of permanent joint damage.
- Awareness of this rare irAE is critical for optimizing patient care in the era of cancer immunotherapy.